期刊
CORONARY ARTERY DISEASE
卷 25, 期 1, 页码 40-44出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCA.0000000000000054
关键词
calcium channel blocker; cardiac syndrome X; combination therapy; statin
资金
- National Natural Science Foundation of China [81100207]
ObjectivesStatins and calcium channel blockers have been proven beneficial toward improvement of endothelial function. The aim of this study was to compare the effect of combination therapy of statin and calcium channel blocker with solo treatment in patients with cardiac syndrome X.Methods and resultsSixty-eight patients with cardiac syndrome X were divided randomly into three groups: fluvastatin (40 mg/day, n=23), diltiazem (90 mg/day, n=22), and combination of fluvastatin (40 mg/day) and diltiazem (90 mg/day, n=23). At the end of 90 days, the coronary flow reserve was improved in the three groups (fluvastatin-treated group: 23.2%; diltiazem-treated group: 12.4%; fluvastatin+diltiazem-treated group: 29.1%, all P<0.05). The time to 1 mm ST segment depression increased significantly in the fluvastatin-treated group (from 24197 to 410 +/- 140 s, P<0.05), the diltiazem-treated group (from 258 +/- 91 to 392 +/- 124 s, P<0.05), and the fluvastatin+diltiazem-treated group (from 250 +/- 104 to 446 +/- 164 s, P<0.05). The improvement in coronary flow reserve and prolonged time to 1 mm ST segment depression in the combination treatment group were more remarkable than in those who received monotherapy. Combination therapy also induced a significant increase (35.6%, P<0.05) in nitric oxide and an apparent reduction (48.7%, P<0.05) in endothelin-1.ConclusionCombination treatment with fluvastatin and diltiazem is more effective on endothelial function and exercise tolerance than solo treatment in patients with cardiac syndrome X. The benefits of these drugs may be related to the elevation of nitric oxide and reduction of endothelin-1. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据